medicalxpress - A gene that is typically active only in reproductive cells may hold the key to new treatments for triple negative breast cancer, according to new research published in the journal Nature Communications. Scientists from the Breast Cancer Now Toby Robins Re…
AI Summary: Researchers have identified HORMAD1, a normally reproductive‑cell gene, as a vulnerability in some triple‑negative breast cancers. Preclinical work suggests exploiting this target could guide patient selection and novel therapies, opening a promising — if early‑stage — route for a tumor type that desperately needs smarter options.
Atezolizumab added to chemoradiation fails to improve limited‑stage SCLC survival / 2 months
Roche’s hoped‑for breast cancer pill fails crucial first‑line trial / 2 months
Romiplostim prevents chemo-induced platelet crashes in phase 3 trial / 2 months
CAR-PRISM trial shows BCMA CAR T effective in high-risk smoldering myeloma / 5 wks
Long‑term immunotherapy appears safe for alveolar soft part sarcoma / 5 wks
Zongertinib emerges as first-line therapy for HER2‑mutant NSCLC / 6 wks
Antoni Ribas receives AACR‑Margaret Foti Award for leadership / 7 wks
StackHealth RSS

StackHealth Time Machine
NorthFeed Inc. Terms and Conditions / Privacy Policy
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.